Sabby Management’s Co-Diagnostics CODX Stock Holding History

Sabby Management’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-9,320	Closed	-$225K	–	99
2019 Q2	$225K	Sell	9,320 -16,458	-64%	-$461K	0.28%	53
2019 Q1	$820K	Buy	+25,778	New	+$928K	0.39%	22

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sabby Management's CODX Position: Q3 2019 in Review

Sabby Management sold out of Co-Diagnostics (CODX) in Q3 2019, closing a stake of 9,320 shares — an estimated $225K sold.

Sabby Management first reported a position in CODX in Q1 2019 and held it in 2 quarters. The position peaked at $820K in Q1 2019. 10 funds tracked by Wall St. Rank hold CODX as of Q3 2019.

Sabby Management reported no remaining Co-Diagnostics position as of Q3 2019 after selling out during the quarter.
Sabby Management sold 9,320 Co-Diagnostics shares in Q3 2019, an estimated $225K.
Sabby Management first reported a position in Co-Diagnostics in Q1 2019 and held it in 2 quarters.
Sabby Management's Co-Diagnostics position peaked at $820K in Q1 2019.
10 funds tracked by Wall St. Rank held Co-Diagnostics as of Q3 2019.

Based on Sabby Management's 13F filing for Q3 2019, filed 15 Nov 2019.